Drug Target Review – Publications

Drug Target Review – Issue 4 2019

This issue includes a discussion on the future of high-throughput screening through collaboration, an analysis of mass spectrometry as a…

By Drug Target Review

Screening In-Depth Focus 2019

In this In-Depth Focus are articles investigating how CROs can help to drive innovation and how CRISPR technologies could be…

By Drug Target Review

Targets In-Depth Focus 2019

The articles in this In-Depth Focus explore a novel technique for studying protein aggregation in Alzheimer's research and explain how…

By Drug Target Review

Hit-To-Lead In-Depth Focus 2019

This in-depth focus features articles on identifying new leads for neglected tropical diseases and how to develop novel peptide hits…

By Drug Target Review

Expert view: Following mitchondrial substrate oxidation pathways to expose novel…

Energy metabolism drives everything we do, so it is no surprise that the more we discover about these metabolic processes,…

By Agilent Technologies

Expert view: Promising methods in kinase screening

Kinase-mediated phosphorylation is a control point for nearly all activity within a cell, making kinases important in many diseases.

By BMG Labtech GmbH

Expert view: Understanding the fast-evolving immune-oncology landscape

The number of immuno-oncology active agents has seen a tremendous boost during the past three years. The 2019 global immuno-oncology…

By Cisbio Bioassays

Expert view – The Octet HTX system: enabling multi-purpose screening…

Current trends in the development of therapeutic biologics suggest that engineered molecules such as bispecific antibodies and antibody-drug conjugates are…

By ForteBio

Expert view: The future of cell expansion for monoclonal antibody…

There is room for improvement in the production of monoclonal antibodies; commercial production needs increased process efficiency and reduced costs.

By Sartorius

Championing genomics in the UK

Professor Sir John Bell, Regius Professor of Medicine at the University of Oxford, delivered a speech at the MHRA’s 14th…

By Nikki Withers (Drug Target Review)

Using droplet digital PCR to monitor the safety of CAR…

CAR T-cell therapy has caused quite a stir in the immunotherapy world, but it is a process that requires precision…

By Dr Ping Jin (Center for Cellular Engineering at National Institutes of Health Clinical Center)

Open innovation – a collaboration between academia and the pharmaceutical…

Increasing numbers of companies in the pharma industry are consolidating their services and outsourcing to CROs to reduce business costs.…

By Dr David Murray (AstraZeneca), Dr Mark Wigglesworth (AstraZeneca), Marian Preston (AstraZeneca)

CRISPR: kick-starting the revolution in drug discovery

Gene editing using the CRISPR system has been established as the most powerful tool in the search for new drugs…

By Dr Pushpanathan Muthuirulan (Harvard University)

Antibody characterisation – an essential researchers’ resource

Central to reproducibility in biomedical research is the ability to use well-characterised and defined reagents. The CPTAC Antibody Portal serves…

By Nikki Withers (Drug Target Review)

Hit-to-lead in neglected diseases – it’s a numbers game

The hit-to-lead journey can be a long endeavour, with many failures along the way. Nikki Withers spoke with DNDi ’s…

By Nikki Withers (Drug Target Review)

Transitioning novel peptide hits into lead compounds

Unlike synthetic compound libraries, natural product hits must be identified and characterised, as the molecule is often unknown. Venom peptides…

By Dr Carol M Trim (Canterbury Christ Church University), Steven A Trim (Venomtech)

A novel approach to unravelling the mysteries of Alzheimer’s

The heterogenous and dynamic nature of protein aggregates makes them a particularly challenging class of structures to study. In this…

By Dr Sean Devenish (Fluidic Analytics), Professor Tuomas Knowles (University of Cambridge)

Advances in mass spectrometry: unlocking the potential of chemical crosslinking…

Chemical crosslinking coupled with mass spectrometry (XL-MS) has been used for many years to study protein structure and function. However,…

By Professor Albert JR Heck Utrecht (University and the Netherlands Proteomics Centre), Professor Alexander Makarov (Thermo Fisher Scientific), Professor Henning Urlaub (Göttingen University Medical Center), Professor Vicki Wysocki (Ohio State University)

Getting precise: how humanised models aid in biologics drug discovery

Humanised immune system (HIS) models have enabled numerous in vivo evaluations of immuno-modulating biologic drugs and ongoing improvements continue to…

By Paul Volden (Taconic Biosciences)

Exploring chemical space for epigenetic drug discovery using AI

It is said that, on average, it takes a new drug 12 years to go from research lab to patient,…

By Alp Tegin Sahin (Fraunhofer-IME), Sheraz Gul (Fraunhofer Institute)

Drug Target Review – Issue 3 2019

Drug Target Review – Issue 2 2019

Drug Target Review – Issue 1 2019

Drug Target Review – Issue 4 2018

Drug Target Review – Issue 3 2018

Drug Target Review – Issue #2 2018

Drug Target Review – Issue #1 2018

Drug Target Review – Issue #4 2017

Drug Target Review – Issue #3 2017

Drug Target Review – Issue #2 2017

Drug Target Review – Issue #1 2017

Drug Target Review – Issue #4 2016

Drug Target Review – Issue #3 2016

Drug Target Review – Issue #2 2016

Drug Target Review – Issue #1 2016

Upstream Bioprocessing In-Depth Focus 2019

Antibodies In-Depth Focus 2019

Genomics In-Depth Focus 2019

Screening In-Depth Focus 2019

Imaging In-Depth Focus 2019

Stem Cell In-Depth Focus 2019

Lab Automation In-Depth Focus 2019

Informatics In-Depth Focus 2019

Assays In-Depth Focus 2019

Application Notes supplement 2018

Hit-to-Lead In-Depth Focus 2018

Screening In-Depth Focus 2018

Targets In-Depth Focus 2018

Upstream Bioprocessing In-Depth Focus 2018

Flow Cytometry In-Depth Focus 2018